Situation Report

WASHINGTON POST      by Kevin Sieff                                                                                      Dec. 19, 2014

FREETOWN, Sierra Leone — To find Andrew Kondoh, walk through the gates of this city’s largest cemetery, where teams in moonsuits bury more than 50 bodies in white plastic bags each day. Look for the man with the wispy goatee and big belly, who is overseeing one of the world’s most chaotic, dangerous graveyards as if he’s done it all before.

That’s because he has.

REUTERS                                                                                              Dec. 19, 2014

GENEVA –  Trials of GlaxoSmithKline's experimental Ebola vaccine are likely to move to a second phase in February, later than previously suggested, after a meeting of national regulators said they needed more information.

The World Health Organization, which hosted a meeting of national regulatory authorities and ethics committees earlier this week, said they had thoroughly discussed all aspects of the proposed trials at the two-day meeting.

"Reviewing countries requested additional documentation from the manufacturer of the vaccine, GlaxoSmithKline, before authorization of the trials," the WHO said in a statement.

Countries where the trials are planned -- Cameroon, Ghana, Mali, Nigeria and Senegal -- should receive and review the additional information by the end of January.

"If these steps are completed to the satisfaction of the national authorities, Phase II trials are likely to begin in February," the statement said.

The GSK vaccine is already undergoing Phase I trials, to check its safety in humans, in Switzerland, Britain, Mali and the United States, and is one of the two leading candidate vaccines for Ebola already undergoing tests.

NBC NEWS by Maggie Fox                                                                                                      Dec. 19, 2014

German doctors think they have another possible drug to add to the Ebola treatment pipeline. It's one already shown to be safe and in trials to treat heart attack victims.

The drug, called FX06, is made using a natural human blood-clotting protein called fibrin. The hope is it can help reduce the leaking of blood vessels that can seriously threaten people with advanced Ebola infections.

The team at Frankfurt University Hospital say it may have helped save a Ugandan doctor they treated, although they note it failed to save a second patient.

Nonetheless, it should be tested, they wrote in the Lancet medical journal.

"Even though the patient was critically ill, we were able to support him long enough for his body to start antibody production and for the virus to be cleared by his body's defenses," said Dr. Timo Wolf, who helped lead the research team. "FX06 could potentially be a valuable agent in contribution to supportive therapy."

Read complete story.

FOOD AND AGRICULTURE ORGANIZATION (FAO)                                                            Dec. 17, 2014

The number of people facing food insecurity due to the Ebola epidemic in Guinea, Liberia and Sierra Leone could top one million by March 2015 unless access to food is drastically improved and measures are put in place to safeguard crop and livestock production, two UN agencies warned today.

The disease's impact is potentially devastating in the three countries already coping with chronic food insecurity, the UN Food and Agriculture Organization (FAO) and the World Food Programme (WFP) said in three country reports published today.

Border closures, quarantines, hunting bans and other restrictions are seriously hindering people's access to food, threatening their livelihoods, disrupting food markets and processing chains, and exacerbating shortages stemming from crop losses in areas with the highest Ebola infection rates, the FAO-WFP reports stressed.

Read complete report.
http://www.fao.org/emergencies/fao-in-action/stories/stories-detail/en/c/273018/